BBA
INZY

Baker Bros. Advisors’s Inozyme Pharma INZY Stock Holding History

Baker Bros. Advisors’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-106,999
Closed -$510K – 120
2022
Q2 		$510K Hold
106,999
– – ﹤0.01% 110
2022
Q1 		$438K Hold
106,999
– – ﹤0.01% 115
2021
Q4 		$730K Hold
106,999
– – ﹤0.01% 120
2021
Q3 		$1.24M Hold
106,999
– – 0.01% 115
2021
Q2 		$1.82M Hold
106,999
– – 0.01% 112
2021
Q1 		$2.12M Hold
106,999
– – 0.01% 114
2020
Q4 		$2.21M Sell
106,999
-11,501
-10% -$274K 0.01% 108
2020
Q3 		$3.12M Buy
+118,500
New +$2.94M 0.01% 92

Other funds holding INZY

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Baker Bros. Advisors's INZY Position: Q3 2022 in Review

Baker Bros. Advisors sold out of Inozyme Pharma (INZY) in Q3 2022, closing a stake of 106,999 shares — an estimated $510K sold.

Baker Bros. Advisors first reported a position in INZY in Q3 2020 and held it in 8 quarters. The position peaked at $3.12M in Q3 2020. 39 funds tracked by Wall St. Rank hold INZY as of Q3 2022.

  • Baker Bros. Advisors reported no remaining Inozyme Pharma position as of Q3 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 106,999 Inozyme Pharma shares in Q3 2022, an estimated $510K.
  • Baker Bros. Advisors first reported a position in Inozyme Pharma in Q3 2020 and held it in 8 quarters.
  • Baker Bros. Advisors's Inozyme Pharma position peaked at $3.12M in Q3 2020.
  • 39 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2022.

Based on Baker Bros. Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.